Y Intercept Hong Kong Ltd Purchases 33,905 Shares of Disc Medicine, Inc. $IRON

Y Intercept Hong Kong Ltd grew its stake in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 361.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 43,287 shares of the company’s stock after acquiring an additional 33,905 shares during the period. Y Intercept Hong Kong Ltd owned about 0.12% of Disc Medicine worth $2,860,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of IRON. JPMorgan Chase & Co. increased its holdings in Disc Medicine by 11.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 843,616 shares of the company’s stock valued at $44,678,000 after purchasing an additional 84,278 shares during the period. Geode Capital Management LLC lifted its position in shares of Disc Medicine by 4.7% in the 2nd quarter. Geode Capital Management LLC now owns 598,589 shares of the company’s stock worth $31,705,000 after purchasing an additional 26,605 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in shares of Disc Medicine by 50.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 450,000 shares of the company’s stock valued at $23,832,000 after purchasing an additional 150,000 shares in the last quarter. Eventide Asset Management LLC raised its stake in Disc Medicine by 69.4% in the second quarter. Eventide Asset Management LLC now owns 308,030 shares of the company’s stock worth $16,313,000 after buying an additional 126,212 shares in the last quarter. Finally, Nantahala Capital Management LLC lifted its holdings in Disc Medicine by 93.9% in the second quarter. Nantahala Capital Management LLC now owns 287,800 shares of the company’s stock worth $15,242,000 after buying an additional 139,409 shares during the period. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Analysts Set New Price Targets

IRON has been the subject of a number of analyst reports. Wedbush restated an “outperform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Truist Financial boosted their target price on Disc Medicine from $86.00 to $114.00 and gave the company a “buy” rating in a research report on Monday, November 10th. UBS Group restated an “overweight” rating on shares of Disc Medicine in a research report on Thursday, January 15th. National Bankshares set a $153.00 price target on shares of Disc Medicine in a report on Friday, October 17th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $120.00 target price on shares of Disc Medicine in a report on Thursday, January 8th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $119.45.

Disc Medicine Price Performance

Shares of IRON stock traded down $2.73 during trading hours on Wednesday, reaching $79.41. The company had a trading volume of 13,232 shares, compared to its average volume of 517,685. The stock has a fifty day moving average of $83.99 and a 200-day moving average of $73.74. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.45 and a current ratio of 23.45. The company has a market capitalization of $3.00 billion, a price-to-earnings ratio of -14.84 and a beta of 0.87. Disc Medicine, Inc. has a 12-month low of $30.82 and a 12-month high of $99.50.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.29). On average, equities analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Insider Buying and Selling

In other news, insider William Jacob Savage sold 13,093 shares of Disc Medicine stock in a transaction on Monday, December 15th. The shares were sold at an average price of $91.22, for a total value of $1,194,343.46. Following the transaction, the insider directly owned 75,702 shares of the company’s stock, valued at $6,905,536.44. The trade was a 14.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kevin Bitterman sold 68,923 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $91.24, for a total value of $6,288,534.52. Following the completion of the transaction, the director owned 14,161 shares in the company, valued at $1,292,049.64. This trade represents a 82.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 275,470 shares of company stock valued at $24,966,170 over the last three months. 3.64% of the stock is currently owned by insiders.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.